REZOLUTE, INC. Notes Payable, Fair Value Disclosure
REZOLUTE, INC. (RZLT) had Notes Payable, Fair Value Disclosure of $683.74 thousand as of 2018-04-03, per its 10-Q filed 2018-12-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2018-12-14
- 2018-04-03: Notes Payable, Fair Value Disclosure $683.74K.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2018-04-03 | $683.74K 10-Q · filed 2018-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |